Clinical trial
Middle Meningeal Artery Embolization Minimizes Burdensome Recurrence Rates After Newly Diagnosed Chronic Subdural Hematoma Evacuation (MEMBRANE)
NCT05327933 is registered in ClinicalTrials.gov with Unfallkrankenhaus Berlin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Middle Meningeal Artery Embolization Minimizes Burdensome Recurrence Rates After Newly Diagnosed Chronic Subdural Hematoma Evacuation (MEMBRANE)
- Lead sponsor
- Unfallkrankenhaus Berlin
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- May 26, 2022
- Completion date
- October 31, 2025
- Enrollment
- 154 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.